Vulvovaginal Candidiasis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Vulvovaginal Candidiasis Clinical Trial market research report provides an overview of the Vulvovaginal Candidiasis clinical trials scenario. This report provides top-line data relating to the clinical trials on Vulvovaginal Candidiasis. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country, phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials.
Regional and Country-Wise Outlook of the Vulvovaginal Candidiasis Clinical Trials Market
The Vulvovaginal Candidiasis clinical trials market is the largest in Asia Pacific, followed by the Middle East and Africa, Europe, North America, and South and Central America.
In a country-wise analysis, as of March 2022, Iran has the highest number of Vulvovaginal Candidiasis clinical trials, followed by China, the US, India, Russia, Canada, Spain, France, Poland, and Australia. Poland has the highest average patient enrollment in Vulvovaginal Candidiasis clinical trials.
G7 countries: Among the G7 (the US, the UK, Japan, Germany, France, Canada, and Italy) countries, Canada has the highest proportion of Vulvovaginal Candidiasis to Infectious Disease clinical trials. Moreover, out of all the clinical trials conducted in the G7 countries, the majority were in the US.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Russia has the highest proportion of Vulvovaginal Candidiasis to Infectious Disease clinical trials. Out of all the clinical trials conducted in the E7 countries, the majority were in China.
Vulvovaginal Candidiasis Clinical Trials Analysis, By Regions
For more regional insights, download a free report sample
Key Sponsor Types in the Vulvovaginal Candidiasis Clinical Trials Market
The key sponsor types in the Vulvovaginal Candidiasis clinical trials market are institution, company, and government. Out of them, company dominates the market.
Vulvovaginal Candidiasis Clinical Trials Market, by Sponsor Types
For more sponsor type insights, download a free report sample
Key Companies in the Vulvovaginal Candidiasis Clinical Trials Market
The key companies in the Vulvovaginal Candidiasis clinical trials market are Scynexis Inc, Viamet Pharmaceuticals Holdings, LLC, Bayer AG, Cidara Therapeutics Inc, Merck & Co Inc, Profem GmbH, NovaDigm Therapeutics Inc, Mirati Therapeutics Inc, Johnson & Johnson, and Jiangsu Hengrui Medicine Co Ltd.
Vulvovaginal Candidiasis Clinical Trials Market, by Companies
To know more about the companies, download a free report sample
Vulvovaginal Candidiasis Clinical Trials Market Report Overview
| Key Regions | Asia-Pacific, Europe, Northern America, Middle East and Africa, and South and Central America |
| Key Countries | Iran, China, The US, India, Russia, Canada, Spain, France, Poland, and Australia |
| Key Sponsor Types | Institution, Company, and Government |
| Key Companies | Scynexis Inc, Viamet Pharmaceuticals Holdings, LLC, Bayer AG, Cidara Therapeutics Inc, Merck & Co Inc, Profem GmbH, NovaDigm Therapeutics Inc, Mirati Therapeutics Inc, Johnson & Johnson, and Jiangsu Hengrui Medicine Co Ltd |
Scope
The report provides:
- A snapshot of the global clinical trials landscape
- Top level data related to the clinical trials by region, country, trial status, trial phase, sponsor type, and end point status
- Reviews of top companies involved and enlists all trials pertaining to the company
- All the unaccomplished trials with the reason for unaccomplishment
- Enrollment trends for the past five years
- Latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The key regions in the Vulvovaginal Candidiasis clinical trials market are Asia-Pacific, Europe, North America, Middle East and Africa, and South and Central America.
The key countries in the Vulvovaginal Candidiasis clinical trials market are Iran, China, the US, India, Russia, Canada, Spain, France, Poland, and Australia.
The key sponsor types in the Vulvovaginal Candidiasis clinical trials market are institution, company, and government.
The key companies in the Vulvovaginal Candidiasis clinical trials market are Scynexis Inc, Viamet Pharmaceuticals Holdings, LLC, Bayer AG, Cidara Therapeutics Inc, Merck & Co Inc, Profem GmbH, NovaDigm Therapeutics Inc, Mirati Therapeutics Inc, Johnson & Johnson, and Jiangsu Hengrui Medicine Co Ltd.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Pharmaceuticals reports